| 今开：2.04 | 昨收：2.02 |
| 最高：2.07 | 最低：1.96 |
| 涨停价：0.0 | 跌停价：0.0 |
| 总市值：2.93546213E8 |
Xeris Biopharma(XERS)05-09 19:25
$Xeris Biopharma(XERS)$ 8-K Current report, items 2.02 and 9.01 Accession Number: 0001867096-24-000062 Act: 34 Size: 257 KB 网页链接查看全文
Xeris Biopharma(XERS)03-07 05:15
$Xeris制药(XERS)$ 10-K Annual report [Section 13 and 15(d), not S-K Item 405] Accession Number: 0001867096-24-000031 Act: 34 Size: 12 MB 网页链接查看全文
Xeris Biopharma(XERS)04-02 05:45
$Xeris Biopharma(XERS)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001867096-24-000039 Size: 6 KB 网页链接查看全文
Xeris Biopharma(XERS)03-07 05:25
$Xeris制药(XERS)$ S-8 Securities to be offered to employees in employee benefit plans Accession Number: 0001867096-24-000032 Act: 33 Size: 97 KB 网页链接查看全文
Xeris Biopharma(XERS)05-10 04:25
$Xeris Biopharma(XERS)$ 10-Q Quarterly report [Sections 13 or 15(d)] Accession Number: 0001867096-24-000065 Act: 34 Size: 52 MB 网页链接查看全文
Xeris Biopharma(XERS)04-24 04:35
$Xeris Biopharma(XERS)$ ARS Annual Report to Security Holders Accession Number: 0001867096-24-000057 Act: 34 Size: 19 MB 网页链接查看全文
Xeris Biopharma(XERS)03-06 20:35
$Xeris制药(XERS)$ 8-K Current report, items 1.01, 2.02, 2.03, and 8.01 Accession Number: 0001867096-24-000024 Act: 34 Size: 332 KB 网页链接查看全文
Xeris Biopharma(XERS)03-19 05:35
$Xeris制药(XERS)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001867096-24-000036 Size: 6 KB 网页链接查看全文
Xeris Biopharma(XERS)04-02 05:55
$Xeris Biopharma(XERS)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001867096-24-000041 Size: 5 KB 网页链接查看全文
Xeris Biopharma(XERS)03-15 09:05
$Xeris制药(XERS)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001867096-24-000034 Size: 5 KB 网页链接查看全文
牛唐2018-06-30 11:35
$Xeris Pharmaceuticals(XERS)$ 公司在美国糖尿病协会上，公布了自己即用型胰岛素注射剂三期的积极结果，在与现有标准疗法glucagon emergency kit的比对中，公司产品在药效和安全性上都有不错表现，下半年计划报NDA查看全文
Xeris Pharmaceuticals(XERS.O)涨超24%，此前获FDA批准将levoketoconazole用于治疗库欣综合征。 网页链接
H.C。 Wainwright:将Xeris Pharmaceuticals(XERS.O)目标价从4.25美元上调至5.40美元。 网页链接
制药公司Xeris Pharmaceuticals(XERS.US)盘前直线拉升，现涨29%；公司宣布FDA批准其Gvoke Kit(胰高血糖素救援笔)的补充新药申请。 网页链接
$Xeris Biopharma(XERS)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001867096-24-000067 Size: 5 KB 网页链接
$Xeris Biopharma(XERS)$ 10-Q Quarterly report [Sections 13 or 15(d)] Accession Number: 0001867096-24-000065 Act: 34 Size: 52 MB 网页链接
$Xeris Biopharma(XERS)$ 8-K Current report, items 2.02 and 9.01 Accession Number: 0001867096-24-000062 Act: 34 Size: 257 KB 网页链接
$Xeris Biopharma(XERS)$ DEF 14A Other definitive proxy statements Accession Number: 0001867096-24-000053 Act: 34 Size: 9 MB 网页链接
$Xeris Biopharma(XERS)$ DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material Accession Number: 0001867096-24-000055 Act: 34 Size: 3 MB 网页链接
$Xeris Biopharma(XERS)$ ARS Annual Report to Security Holders Accession Number: 0001867096-24-000057 Act: 34 Size: 19 MB 网页链接
$Xeris Biopharma(XERS)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001867096-24-000043 Size: 6 KB 网页链接
$Xeris Biopharma(XERS)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001867096-24-000041 Size: 5 KB 网页链接
$Xeris Biopharma(XERS)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001867096-24-000039 Size: 6 KB 网页链接
$Xeris制药(XERS)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001867096-24-000036 Size: 6 KB 网页链接